126 related articles for article (PubMed ID: 14518756)
21. Charles Bonnet syndrome precipitated by brimonidine tartrate eye drops.
Tomsak RL; Zaret CR; Weidenthal D
Br J Ophthalmol; 2003 Jul; 87(7):917. PubMed ID: 12812898
[No Abstract] [Full Text] [Related]
22. Allergic reactions to brimonidine in patients treated for glaucoma.
Blondeau P; Rousseau JA
Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
24. Selectivity of site of action and systemic effects of topical alpha agonists.
Robin AL; Burnstein Y
Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
[TBL] [Abstract][Full Text] [Related]
25. Dilute brimonidine to improve patient comfort and subconjunctival hemorrhage after LASIK.
Pasquali TA; Aufderheide A; Brinton JP; Avila MR; Stahl ED; Durrie DS
J Refract Surg; 2013 Jul; 29(7):469-75. PubMed ID: 23820229
[TBL] [Abstract][Full Text] [Related]
26. The teardrop sign: a rare dermatological reaction to brimonidine.
Scruggs JT; Whiteside-Michel J; Brodsky MC
Br J Ophthalmol; 2000 Jun; 84(6):671-2. PubMed ID: 10896417
[No Abstract] [Full Text] [Related]
27. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
28. Failure of naloxone to reverse brimonidine-induced coma in an infant.
Sztajnbok J
J Pediatr; 2002 Apr; 140(4):485-6; author reply 486. PubMed ID: 12006970
[No Abstract] [Full Text] [Related]
29. Systemic side effects of ophthalmic drops.
Levy Y; Zadok D
Clin Pediatr (Phila); 2004; 43(1):99-101. PubMed ID: 14968900
[TBL] [Abstract][Full Text] [Related]
30. Brimonidine tartrate: a one-month dose response study.
Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
[TBL] [Abstract][Full Text] [Related]
31. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
Korsch E; Grote A; Seybold M; Soditt V
Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
[No Abstract] [Full Text] [Related]
32. Brimonidine and pupillary diameter.
Mastropasqua L; Carpineto P; Ciancaglini M
Ophthalmology; 1998 Aug; 105(8):1352-3. PubMed ID: 9709738
[No Abstract] [Full Text] [Related]
33. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
34. A paradoxical ocular effect of brimonidine.
Mushtaq B; Sardar J; Matthews TD
Am J Ophthalmol; 2003 Jan; 135(1):102-3. PubMed ID: 12504711
[TBL] [Abstract][Full Text] [Related]
35. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
36. [Anterior uveitis and topical brimonidine: a case report].
Velasque L; Ducousso F; Pernod L; Vignal R; Deral V
J Fr Ophtalmol; 2004 Dec; 27(10):1150-2. PubMed ID: 15687926
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of brimonidine tartrate 0.2% ophthalmic solution in reducing halos after laser in situ keratomileusis.
Lee JH; You YS; Choe CM; Lee ES
J Cataract Refract Surg; 2008 Jun; 34(6):963-7. PubMed ID: 18499002
[TBL] [Abstract][Full Text] [Related]
38. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
39. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
40. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
Serle JB
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
